Related Experiment Video
Updated: Jul 13, 2026
10:44
Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
Published on: March 28, 2017
Cytochrome P450 3A and their regulation
Oliver Burk1, Leszek Wojnowski
1Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Auerbachstrasse 112, 70376, Stuttgart, Germany.
Naunyn-Schmiedeberg'S Archives of Pharmacology
|October 22, 2003
Summary
Cytochrome P450 3A (CYP3A) enzymes metabolize many drugs and toxins. Understanding genetic variations in CYP3A expression can personalize drug therapy and identify cancer risks.
Area of Science:
- Pharmacology and Toxicology
- Genetics and Molecular Biology
Background:
- Cytochrome P450 3A (CYP3A) enzymes are crucial for metabolizing 45-60% of drugs, steroid hormones, toxins, and carcinogens.
- Individual variability in hepatic CYP3A expression and activity is well-documented and linked to adverse drug interactions and potential cancer predisposition.
Purpose of the Study:
- To review the current understanding of CYP3A genetics and expression regulation.
- To highlight the significance of identifying predictive markers for individual CYP3A activity.
Main Methods:
- Review of existing literature on CYP3A genetics and regulation.
- Focus on recently identified markers for CYP3A5 and CYP3A7 polymorphisms.
Main Results:
- CYP3A enzymes play a significant role in drug metabolism and the processing of various endogenous and exogenous compounds.
- Genetic polymorphisms in CYP3A5 and CYP3A7 have been identified as potential markers for individual CYP3A activity.
Conclusions:
- Elucidating factors controlling individual CYP3A activity can enable personalized medicine and risk stratification for certain cancers.
- New genetic markers are expected to accelerate the development of probes for individual CYP3A isozyme activity and function.
Related Concept Videos
01:19Regulation of Metabolism
Cellular needs and conditions vary from cell to cell and change within individual cells over time. For example, the required enzymes and energetic demands of stomach cells are different from those of fat storage cells, skin cells, blood cells, and nerve cells. Furthermore, a digestive cell works much harder to process and break down nutrients during the time that closely follows a meal compared with many hours after a meal. As these cellular demands and conditions vary, so do the amounts and...
01:17Drug Metabolism: Phase I Reactions
A phase I reaction is a biochemical process that introduces a functionally reactive polar group to a substance. This transformation predominantly occurs in the liver, facilitated by the cytochrome P450 system of hemoproteins situated in the lipophilic endoplasmic reticulum of cells. The metabolite generated through this process can have varying polarities. If it is sufficiently polar, it can be easily excreted in the urine due to its water compatibility. However, if the metabolite is nonpolar,...
01:25Pharmacokinetics: Drug–Drug Interactions
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:25Bioactivation and Tissue Toxicity
Bioactivation is a metabolic process that transforms less reactive substances into highly reactive metabolites, initiating tissue toxicity. This transformation can lead to various toxic effects, including carcinogenesis and teratogenesis. Reactive metabolites are classified into two main types: electrophiles and free radicals.Electrophiles are electron-deficient species and are produced primarily by the enzyme cytochrome P-450 during the metabolism of compounds containing carbon, nitrogen, or...